Monopar Therapeutics announces new data from study of ALXN1840

Monopar Therapeutics (MNPR) announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease will be presented at the 150th American Neurological Association, ANA, Annual Meeting on September 14-15, 2025. The poster and oral presentations will be delivered by Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan. Key findings to be presented at ANA include: Sustained Neurological Improvement: Statistically significant neurologic improvement from baseline on the Unified Wilson Disease Rating Scale Part II and Part III was sustained over 6 years. Crossover Benefit: Patients who crossed over from standard of care to ALXN1840 showed additional neurological improvement, including a majority of patients who had worsened on SoC demonstrating a reversal on ALXN1840. Psychiatric Outcomes: Statistically significant psychiatric improvement from baseline was sustained over multiple years, as measured by the Brief Psychiatric Rating Scale. Consistency Across Trials: Neurological benefit was observed consistently across multiple independent studies. Favorable Safety Profile: Across more than 645 patient-years on ALXN1840, less than 1% of patients experienced a drug-related neurological serious adverse event.